BIIB vs IMUX
BIIB: Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease. IMUX: Immunic is a late-stage biotech developing oral small-molecule therapies for multiple sclerosis and gastrointestinal diseases with Phase 3 data expected in 2026.
Side-by-side fundamentals
| Metric | BIIB | IMUX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $197.74 | $15.11 | |
| Market cap as of 2026-07-23 | $29.8B | $206M | |
| P/E as of 2026-07-23 | 21.75 | n/a | |
| PEG as of 2026-07-23 | 10.24 | n/a | |
| Net margin as of 2026-07-23 | +13.8% | n/a | |
| Gross margin as of 2026-07-23 | +75.5% | n/a | |
| Operating margin as of 2026-07-23 | +17.5% | n/a | |
| ROE as of 2026-07-23 | +7.5% | -130.3% | BIIB higher |
| ROA as of 2026-07-23 | +4.7% | -132.0% | BIIB higher |
| Debt / equity as of 2026-07-23 | 0.34 | 0.00 | IMUX lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.16 | 1.39 | |
| 1-year return as of 2026-07-22 close | +54.7% | +61.4% | IMUX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.